Pain‐free walking distance · intermittent claudication
1 finding from 1 review
Quality of Life: SF‐36 (physical component) · intermittent claudication
1 finding from 1 review
Health‐related quality of life (mental) · intermittent claudication
1 finding from 1 review
Resolution of daytime urinary incontinence · children aged 5 to 16 years with daytime urinary incontinence
Voiding education with uroflow feedback and urotherapy showed no clear difference in resolution of daytime urinary incontinence at 6 to 12 months after 6… compared with urotherapy alone (low certainty).
1 finding from 1 review
Frequency of incontinence episodes · children aged 5 to 16 years with daytime urinary incontinence
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Objective measurement of volume of incontinent episodes · children aged 5 to 16 years with daytime urinary incontinence
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Resource implications (e.g. cost of incontinence management methods) · children aged 5 to 16 years with daytime urinary incontinence
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life measurements · children aged 5 to 16 years with daytime urinary incontinence
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects · children aged 5 to 16 years with daytime urinary incontinence
1 finding from 1 review
Quality of life: not measured · treatment of relapsed epithelial ovarian cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall survival · treatment of relapsed epithelial ovarian cancer
EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy showed no clear difference in overall survival compared with chemotherapy alone (low certainty).
1 finding from 1 review
Progression‐free survival · treatment of relapsed epithelial ovarian cancer
It is very uncertain whether EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy changes progression‐free survival compared with chemotherapy alone (very low certainty).
1 finding from 1 review
Grade 3 to 4 rash · treatment of relapsed epithelial ovarian cancer
It is very uncertain whether EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy changes toxicity: grade 3 or 4 rash compared with chemotherapy alone (very low certainty).
1 finding from 1 review
Toxicity: grade 3 or 4 nausea ± vomiting · treatment of relapsed epithelial ovarian cancer
It is very uncertain whether EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy changes toxicity: grade 3 or 4 nausea ± vomiting compared with chemotherapy alone (very low certainty).
1 finding from 1 review
Toxicity: grade 3 or 4 fatigue · treatment of relapsed epithelial ovarian cancer
It is very uncertain whether EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy changes toxicity: grade 3 or 4 fatigue compared with chemotherapy alone (very low certainty).
1 finding from 1 review
Toxicity: cardiac toxicity (any grade) · treatment of relapsed epithelial ovarian cancer
EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy showed no clear difference in toxicity: cardiac toxicity (any grade) compared with chemotherapy alone (low certainty).
1 finding from 1 review
Major cardiovascular event Physicians · Adults with chronic kidney disease not requiring dialysis
Statin therapy leads to lower major cardiovascular events (MACE) compared with placebo or standard of care (high certainty).
1 finding from 1 review
Death · Adults with chronic kidney disease not requiring dialysis
Statin therapy leads to lower death compared with placebo or standard of care (high certainty).
1 finding from 1 review
Rhabdomyolysis · Adults with chronic kidney disease not requiring dialysis
It is very uncertain whether statin therapy changes rhabdomyolysis compared with placebo or standard of care (very low certainty).
1 finding from 1 review
Myocardial infarction · Adults with chronic kidney disease not requiring dialysis
Statin therapy probably leads to lower myocardial infarction compared with placebo or standard of care (moderate certainty).
1 finding from 1 review